Skip to main content
Fig. 7 | Diabetology & Metabolic Syndrome

Fig. 7

From: Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Fig. 7

Gene expression of lipid metabolism in the liver of the five groups. Normalized mRNA expression of fatty acid synthase (FAS) (a), acetyl-CoA carboxylase (ACC) 1 (b), peroxisome proliferator-activated receptor (PPAR) α (c), and acyl-coenzyme A oxidase (ACOX)1 (d). Data are mean ± SD. *P < 0.05, P < 0.01, P < 0.001 vs. control; §P < 0.05, ||P < 0.01, P < 0.001 vs. vehicle; #P < 0.05, **P < 0.01, ††P < 0.001 vs. Linagliptin alone

Back to article page